Navigation Links
Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor

CAMBRIDGE, MA November 11, 2009 Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival. This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities. There are estimated to be more than 1,500 transcription factors in the human genome, regulating key biological processes important in diseases such as arthritis, asthma, diabetes, infectious diseases, and cancer .

In their research published in Nature, Drs. Bradner and Verdine showed in multiple models, including T-cell acute lymphoblastic leukemia (T-ALL), that Stapled Peptides achieved tight direct binding to the Notch transcription factor complex, preventing the assembly of a functional transcription complex by the Notch1 oncogene. Further in vivo data show that direct and specific antagonism of the Notch multi-protein complex in the nucleus of cancer cells suppressed the transcription of many growth stimulating proteins such as Myc, thereby leading to cancer cell death. Potent, specific pathway inhibition was determined using genome-wide transcriptional signatures, first in vitro and later validated as biomarker studies in vivo. The direct inhibition achieved did not result in gastrointestinal toxicity, suggesting a viable therapeutic window for Stapled Peptides, without the limitations previously observed with upstream inhibitors of Notch.

"Transcription factors are among the most desirable and validated therapeutic targets in cancer, yet they are among the most elusive targets in cancer drug discovery," said James Bradner, MD,, Division Of Hematologic Neoplasia, Dana-Farber Cancer Institute. "Our research shows, for the first time, how assembly of the Notch multi-protein transcription factor complex can be inhibited in the nucleus of a cancer cell with a stapled peptide, leading to cancer cell death. Using stapled peptides to target transcription factors opens a potential new path for discovering novel and effective therapies for patients."

A growing body of research describes the critical role that transcription factors play in biological pathways implicated in a broad array of human diseases. In the past 25 years, for example, the 20 most-cited transcription factors have been referenced in the scientific literature an estimated 100,000 timesi. In cancer biology, it has been shown that more than 50% of T-cell acute lymphoblastic leukemias (T-ALL) have activating mutations in Notch . However, the vast majority of transcription factors lack an appropriate binding pocket for targeting by small molecules. Moreover, most transcription factors reside within cells and so are not suitable for antibody-based therapies. Stapled Peptides have now been shown to inhibit a previously-undruggable transcription factor at a therapeutically meaningful level.

"These results are tantamount to a declaration of open season on transcription factors," said Gregory L. Verdine, PhD, Erving Professor of Chemistry, Harvard University and co-chair of Aileron Therapeutics' scientific advisory board. "While the vast majority of transcription factors are not druggable with current small molecule or biologic modalities, many features of the protein-protein interaction represented by Notch are similar to other transcription factor assemblies, giving us good reason to expect that this technology will be useful for other currently undruggable targets across diseases such as cancer, inflammation, obesity, and infection."

"The publication of a second major research article in Nature within a year demonstrates the momentum and potential for development of Stapled Peptides as a new drug modality," said Joseph Yanchik, III, Chief Executive Officer of Aileron Therapeutics. "Stapled Peptides designed to target important biologic but previously undruggable transcription factors, such as Notch, is a major focus of Aileron's R&D effort and is of significant interest as one of our potential early clinical development programs."

In a study published in Nature in October 2008 titled "BAX Activation is Initiated at a Novel Interaction Site," Aileron Therapeutics collaborators at the Dana Farber Cancer Institute demonstrated that a Stapled Peptide was able to uniquely target a new and fundamental activation mechanism of the programmed cell death or "apoptotic" pathway.

Aileron has developed Stapled Peptides designed to target specific transcription factors across multiple therapeutic areas, and is advancing these compounds in its preclinical programs.


Contact: Kathryn Morris
Yates Public Relations

Related medicine news :

1. Old Colony Elder Services Collaborates with The Charity Guild of Brockton to Offer "Special Foods for Special People" Program
2. UNTHSC Collaborates With Law Enforcement to Provide Alternatives to Dallas Prostitutes
3. WellPoint Collaborates with RedBrick Health to Create Integrated, Behavior-Based Wellness and Incentives Programs
4. Blue Cross and Blue Shield of Texas Collaborates With Five Blue Plans to Increase Transparency, Expand Access to Health Care Cost Information
5. Partnership Collaborates on HIE for Interoperability of Electronic Health Records and Patient Data in Ohio
6. Michigan State Medical Society Collaborates With Microsoft to Expand Health Care Technology in Michigan
7. Apollo Health Street Collaborates with Client to Develop a CCHIT-Certified 08 Ambulatory EMR
8. Collaborates With, Providing Quality Awareness Sponsorships to #1 Breast Cancer Resource Online
9. Impac Software Collaborates With the National Comprehensive Cancer Network to Improve Patient Care
10. Healthbase Collaborates with WellPoint to Bring Affordable Medical Tourism Solutions
11. Pathwork Diagnostics Collaborates With Guys and St Thomas on Tissue of Origin Test Validation in the UK
Post Your Comments:
(Date:10/13/2015)... Alexandria, Va. — , ... ... Military Officers Association of America (MOAA) will hold its 2015 ... Highlights include a free military career fair; informational seminars; a ... chairman of the Joint Chiefs of Staff; and the Community ...
(Date:10/13/2015)... ... October 13, 2015 , ... Vision Group Holdings, the ... San Diego, California. With brands including The LASIK Vision Institute and TLC Laser Eye ... the nationwide leader in laser vision correction. , Global Laser Vision will continue to ...
(Date:10/13/2015)... Nashville, Tennessee (PRWEB) , ... October 13, 2015 ... ... owned leader of anesthesia and pain management services, today announced its partnership with ... the partnership integrates data from disparate systems and organizes the data into an ...
(Date:10/13/2015)... Texas (PRWEB) , ... October 13, 2015 , ... Symposium ... for the 19th annual Dallas Cosmetic Symposium to be held March 2nd and 3rd, ... place immediately afterwards, draws plastic surgeons and cosmetic physicians from around the world. , ...
(Date:10/13/2015)... ... October 13, 2015 , ... e-con Systems Inc., a leading embedded design services ... the industry’s first RGB-IR pixel format camera with a USB 3.0 interface and ... family of UVC USB 3.0 cameras, is based on the 1/3-inch OV4682 - a ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)...  Graduate students across the country, with an ... soon have the opportunity to learn about a ... discovery and development process. Eli Lilly and Company ... leaders from academic institutions to create an elective ... Drug Development."  Lilly will formally unveil the eLearning ...
(Date:10/13/2015)... SAN FRANCISCO , October 13, 2015 ... expected to reach USD 26.8 billion by 2022, according ... Anesthesia and respiratory devices, owing to their capability to ... expected to witness a substantial growth. --> ... reach USD 26.8 billion by 2022, according to a ...
(Date:10/13/2015)... , Oct. 13, 2015   Micell Technologies ... DESSOLVE I and II trials of its MiStent Sirolimus ... ® ) were presented at the 27th Annual ... San Francisco , October 11-15. TCT ... cardiovascular medicine. MiStent SES was designed to optimize vessel ...
Breaking Medicine Technology: